Pills are also easier to manufacture than injectable pens, which could help avoid the frustrating supply problems that slowed earlier GLP-1 launches
Possible effects include nausea, reflux, constipation, or fatigue all of which are monitored closely and managed conservatively
That last statement is significant
The Endocrine Society's 2023 obesity pharmacotherapy guideline states: "When a patient does not achieve adequate weight loss on a maximally tolerated dose of a GLP-1 receptor agonist, switching to an agent with a broader receptor profile is a reasonable escalation strategy, provided the patient is counseled on the investigational status of newer agents" [5]
Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S
At 0.5 mg per week, most people report minimal to no GI symptoms